SCHEMBL17848847

SCHEMBL17848847

CCCC(C)(C)C(CC(=O)O)C(=O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.36
HSPD1 P10809 1/20 0.35
BLM P54132 1/20 0.35
HSPE1 P61604 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
GPR84 Q9NQS5 4/20 0.34
HDAC1 Q13547 2/20 0.33
HDAC2 Q92769 2/20 0.33
CHRM1 P11229 1/20 0.33
AKR1A1 P14550 1/20 0.33
CHRM3 P20309 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
ADRA1A P35348 1/20 0.33
HRH1 P35367 1/20 0.33
DRD3 P35462 1/20 0.33
SLC6A3 Q01959 1/20 0.33
CA2 P00918 1/20 0.33
MAPK1 P28482 1/20 0.33
FFAR3 O14843 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24401338 0.88 GPR84 (0.40) HSPD1BLMHSPE1GPR84CA2
SCHEMBL28248774 0.85 GPR84 (0.46) TDP1HSPD1BLMHSPE1GPR84
SCHEMBL3884302 0.83 TDP1 (0.39) TDP1HSPD1BLMHSPE1SMN1; SMN2
SCHEMBL3419467 0.82 TDP1 (0.34) TDP1SMN1; SMN2SLC22A6PGD
SCHEMBL26857529 0.80 MAPT (0.36) GPR84SLC22A6PGDALDH1A1
SCHEMBL16382108 0.79 CHRM1 (0.33) TDP1HSPD1BLMHSPE1HDAC1
SCHEMBL28501008 0.78 TDP1 (0.34) TDP1HSPD1BLMHSPE1SMN1; SMN2
SCHEMBL14533583 0.76 CA2 (0.31) TDP1HSPD1BLMHSPE1HDAC1
SCHEMBL23964029 0.75 TDP1 (0.36) TDP1SMN1; SMN2CHRM1ADRA1ASLC22A6
SCHEMBL8853350 0.75 TDP1 (0.43) TDP1HSPD1BLMHSPE1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3233889-B1 ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS SHANGHAI MICURX PHARMACEUTICAL CO LTD (CN) 2022-07-06 EP disclosed
EP-3233889-A2 ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS Micurx Pharmaceuticals, Inc. (US) 2017-10-25 EP disclosed
US-9771394-B2 Antimicrobial polymyxins for treatment of bacterial infections MICURX PHARMACEUTICALS, INC. (KY) 2017-09-26 US disclosed
US-20160185823-A1 ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS MICURX PHARMACEUTICALS, INC. 2016-06-30 US disclosed
WO-2016100578-A2 ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS MICURX PHARMACEUTICALS, INC. (US) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160185823-A1 ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS VIP, AQP1, PEF1 TDP1 4751/4885HSPD1 1338/4885BLM 1188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.